key: cord-0720079-98xisxg7
authors: O’Brien, Connor; Ning, Ning; McAvoy, James; Mitchell, James E.; Kalwani, Neil; Wang, Paul; Nguyen, Duy; Reejhsinghani, Risheen; Rogers, Angela; Lorenzo, Javier
title: Electrical Storm in COVID-19
date: 2020-05-29
journal: JACC Case Rep
DOI: 10.1016/j.jaccas.2020.05.032
sha: 97310c36c202d4165607fd6d23c3ff3d5e37fd74
doc_id: 720079
cord_uid: 98xisxg7

Abstract COVID-19 is a global pandemic caused by SARS-CoV-2. Infection is associated with significant morbidity and mortality. Individuals with pre-existing cardiovascular disease or evidence of myocardial injury are at risk for severe disease and death. Little is understood about the mechanisms of myocardial injury or life-threatening cardiovascular sequelae.

DCCV = direct current cardioversion HFpEF = heart failure with preserved ejection fraction LAD = left anterior descending LVEF = left ventricular ejection fraction NSR = normal sinus rhythm PCI = percutaneous coronary intervention PMVT = polymorphic ventricular tachycardia PVC = premature ventricular contraction SARS-CoV-2 = Severe Acute Respiratory Syndrome Coronavirus-2

An 82-year-old woman presented from her skilled nursing facility to our emergency department for evaluation of two days of cough, fever to 38.3 o C, and dyspnea requiring 6L nasal canula to maintain peripheral oxygen saturation of 92%.

Her medical history includes mild asthma, HFpEF, CAD (PCI 2010), paroxysmal AF, hypertension, obesity, and total hip arthroplasty one-month prior.

Her differential diagnosis included bacterial/viral pneumonia, acute on chronic HFpEF, pulmonary embolism, and COVID-19.

On arrival she was hemodynamically stable: heart rate 62, blood pressure 130/84 mmHg, respiratory rate of 18, and oxygen saturation 98% on 6L nasal canula. Physical exam noted bilateral rales. Chest x-ray showed patchy bilateral consolidations with mild interstitial edema ( Figure 1) . A CT pulmonary angiogram revealed no pulmonary embolism but bilateral interlobular septal thickening and peripheral ground glass opacities most prominent in the posterior and lower zones. Labs were remarkable for a WBC of 6.0 k/µL, absolute lymphocyte count of 350/µL, hemoglobin 8.8mg/dL (7.7mg/dL one month prior), hyponatremia to 129mmol/L, ferritin of 1,167ng/mL, NT-proBNP of 721pg/mL, and CRP of 4.9mg/dL (Fig 2a) .

Remaining labs were within normal limits. A nasopharyngeal swab was sent for SARS-CoV-2 and respiratory viruses, blood cultures were collected, vancomycin and cefepime were started, and the patient was admitted to a negative pressure room.

Within hours the patient developed increased work of breathing and hypoxia requiring intubation. She was sedated with propofol and hydromorphone infusions; suspected sedationrelated hypotension was treated with norepinephrine and vasopressin infusions. An echocardiogram revealed an LVEF of 68%, estimated right ventricular systolic pressure of 33mmHg, right atrial pressure of 8mmHg, and small left ventricular end-diastolic volume of 40mL. She developed AF with rapid ventricular response with rates to 155bpm. The ventricular response rate was controlled with an amiodarone infusion. Serial troponins were not elevated and ECG revealed AF but was otherwise normal (Figure 1 ). Propofol was transitioned to dexmedetomidine allowing vasopressor cessation. She converted to NSR; amiodarone infusion was converted to oral.

She was mechanically ventilated on a volume control mode with 50% FiO2 and PEEP of 10 cm H2O with inhaled nitric oxide for hypoxemia support. Tidal volume was set to 340mL (6mL/kg based on ideal body weight). Plateau pressure was 24 cmH 2 O with a driving pressure of 14 cmH 2 O. Proning protocol was initiated with at least 12 hours prone as well as active diuresis to maintain a CVP <10 mmHg. On hospital day 1 her SARS-CoV-2 PCR returned positive, and she was enrolled in a remdesivir trial. Vancomycin and cefepime were stopped on day 3 and 4, respectively.

On day 10, she developed a persistent fever of 38.1 o C and vasopressor requirement ( Figure 2B) . Chest x-ray showed worsening consolidation of her right lower and right upper lung fields. Vancomycin and cefepime were resumed. The patient's static pulmonary compliance decreased and oxygen requirements rose to 70% FiO2 and PEEP of 12 cmH 2 O to maintain a saturation of 92%. Respiratory and blood cultures grew Pseudomonas aeruginosa. Antibiotics were narrowed to piperacillin-tazobactam. Her creatinine increased gradually to 2.05mg/dL on day 12.

On ICU day 13 she developed multimorphic ventricular ectopy ( Figure 3A CVP remained less than 10mmHg. Given concern for borderline QTc prolongation, all QTcprolonging medications (amiodarone and trazodone) were stopped. Lidocaine infusion was initiated, and metoprolol was added to suppress ectopy. A follow-up echocardiogram showed no evidence of ventricular dysfunction, chamber enlargement or wall motion abnormality. Electrical instability precluded cardiac MRI.

The patient continued to have early coupled PVCs initiating episodes of sustained PMVT despite shortening of her QTc interval to 400 -440 msec, heart rate of 60 to 70 bpm, and no evidence of ischemia with stable ECGs and down-trending troponin levels (Figures 1 and 2A) . 

This case illustrates the clinical challenges of managing cardiovascular complications of COVID-19 infection. COVID-19 is known to enter cells via the angiotensin converting enzyme II receptor (1), which is expressed in myocardium raising concern that the virus could directly infect the heart. Studies of SARS-CoV-1 demonstrated replication in myocardium(2), raising suspicions that viral myocarditis may explain the high degree of morbidity and mortality seen in COVID-19 patients with evidence of myocardial injury.

While the evidence for myocarditis is biologically plausible, ARDS is a complex biological state. Furthermore COVID-19 myocardial injury has a diversity of presentations (3, 4) . Many of the patients suffering myocardial injury during COVID-19 have pre-existing cardiovascular disease, predisposing them to type 2 myocardial infarction, stress induced cardiomyopathy, and secondary cardiac injury. While case reports have described acute cardiovascular collapse with troponin elevation and imaging evidence of myocardial inflammation (4), many cases have a more protracted course averaging two weeks (3) . While direct viral injury is possible, drivers like cytokine storm, critical illness, and ischemia are plausible.

Our case illustrates the occurrence of malignant ventricular arrhythmias in a patient with COVID-19 related multi-organ dysfunction, and the association of cardiac complications with poor clinical outcome. Based on clinical and post-mortem analysis viral myocarditis, plaque rupture, microvascular thrombosis, and QT-prolongation appear to be unlikely drivers. Cytokine storm is possible, but her down-trending CRP, less than two-fold increase in d-dimer, normal white count, and afebrile state at the time of arrhythmia onset do not support this theory.

Postulating whether Remdesivir contributed to this electrical storm remains challenging given limited experience. However, a relationship seems unlikely as treatment ended on hospital day 5 and drug half-life is reported as 35-hours(5). Our case likely describes a multifactorial epiphenomenon emerging from vulnerable patient substrate under strain from protracted critical illness.

While myocarditis and cytokine storm may be significant drivers of morbidity and mortality in COVID-19, this case highlights that not all cardiovascular complications are the result of direct viral injury or systemic inflammation specific to SARS-CoV-2. Prolonged critical illness likely contributes significantly to the high incidence of cardiovascular insults.

Determining specific pathophysiologic mechanisms of cardiac sequelae is essential to guiding therapy in this critically ill population. 

The differential for electrical storm in COVID-19 remains broad. Myocarditis and cytokine storm may not be universal drivers of cardiac sequelae in COVID-19. Management of these arrhythmias requires consultation with expert, multi-disciplinary teams

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)

WHO Ad-hoc Expert Consultation on clinical trials for Ebola Therapeutics. Appendix 4